Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants

Sep 8, 2023

Happy to share our latest publication about the potential health and economic impact of switching the current 13-valent Pneumococcal Conjugate Vaccine (PCV13) among the Greek  paediatric Vaccination programme with higher-valent conjugate vaccines.

Find out more at: Vaccines (Basel)


Archive Per Year